Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $300,004,000 | $301,965,000 | $279,037,000 | $266,257,000 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Cost of Goods Sold | $128,977,000 | $123,256,000 | $112,950,000 | $109,671,000 |
| Gross Profit | $171,027,000 | $178,709,000 | $166,087,000 | $156,586,000 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| R&D Expenses | $24,103,000 | $25,416,000 | $28,297,000 | $26,377,000 |
| G&A Expenses | $87,967,000 | $91,529,000 | $96,257,000 | $84,499,000 |
| SG&A Expenses | $87,967,000 | $91,529,000 | $96,257,000 | $84,499,000 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $12,077,000 | $23,223,000 | $44,623,000 | $9,824,000 |
| Operating Expenses | $124,147,000 | $140,168,000 | $169,177,000 | $120,700,000 |
| Operating Income | $46,880,000 | $38,541,000 | -$3,090,000 | $35,886,000 |
| % Margin | 15.6% | 12.8% | -1.1% | 13.5% |
| Other Income/Exp. Net | $601,000 | -$8,667,000 | -$2,709,000 | -$270,000 |
| Pre-Tax Income | $47,481,000 | $29,874,000 | -$5,799,000 | $35,616,000 |
| Tax Expense | $11,628,000 | $3,171,000 | $9,184,000 | $8,427,000 |
| Net Income | $36,256,000 | $26,642,000 | -$14,948,000 | $27,218,000 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS | 103.98 | 72.62 | -38.58 | 68.07 |
| % Growth | 43.2% | 288.2% | -156.7% | – |
| EPS Diluted | 103.68 | 72.37 | -38.58 | 67.97 |
| Weighted Avg Shares Out | 348,605 | 366,890 | 387,420 | 399,775 |
| Weighted Avg Shares Out Dil | 349,694 | 368,136 | 387,420 | 400,457 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,002,000 | $1,572,000 | $1,153,000 | $2,543,000 |
| Interest Expense | $2,716,000 | $2,664,000 | $1,499,000 | $1,209,000 |
| Depreciation & Amortization | $8,812,000 | $18,178,000 | $17,249,000 | $17,055,000 |
| EBITDA | $59,009,000 | $50,716,000 | $12,949,000 | $52,930,000 |
| % Margin | 19.7% | 16.8% | 4.6% | 19.9% |